|
|
|
| Evaluation of the 8th AJCC staging system for pathologically versus clinically staged pancreatic adenocarcinoma: A time to revisit a dogma? |
| Omar Abdel-Rahman |
Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
E-mail address: omar.abdelrhman@med.asu.edu.eg |
|
|
|
Abstract Background: The 8th edition of the American Joint Committee on Cancer (AJCC) staging system for pancreatic exocrine adenocarcinoma has been released. The current study seeks to assess the 7th and 8th editions among patients registered within the surveillance, epidemiology and end results (SEER) database.
Methods: SEER database (2010–2013) has been accessed through SEER∗Stat program and AJCC 8th edition stages were reconstructed utilizing the collaborative stage descriptions. Kaplan–Meier analysis of overall survival and pancreatic cancer-specific survival analyses (according to both 7th and 8th editions and according to whether pathological or clinical staging were conducted) has been performed. Multivariate analysis of factors affecting pancreatic cancer-specific survival was also conducted through a Cox proportional hazard model.
Results: A total of 18 948 patients with pancreatic adenocarcinoma were identified in the period from 2010–2013. Pancreatic cancer-specific survival among pathologically staged patients and according to the 8th edition showed significant differences for all pair wise comparisons among different stages (P<0.0001) except for the comparison between stage IA and stage IB (P=0.307) and the comparison between stage IB and stage IIA (P=0.116). Moreover, P value for stage IA vs IIA was 0.014; while pancreatic cancer-specific survival according to the 7th edition among pathologically staged patients showed significant differences for all pair wise comparisons among different stages (P<0.0001) except for the comparison between IA and IB (P=0.072), the comparison between stage IIA and stage IIB (P=0.065), the comparison between stage IIA and stage III (P=0.059) and the comparison between IIB and III (P=0.595). Among clinically staged patients (i.e. those who did not undergo initial radical surgery), the prognostic performance of both 7th and 8th stages for both overall survival and pancreatic cancer-specific survival was limited.
Conclusion: There is clearly a need to have two staging systems for pancreatic adenocarcinoma: pathological and clinical staging systems.
|
|
|
|
|
|
|
|
|
2018, Vol. 17 
